SB is not even near a Phase I clinical trial, so the effectiveness of their molecule is far from being known.
The article referenced for you details the preliminary findings of a Phase I study: (not related to mRNA tech)
"The phase one trial by the Institute of Cancer Research (ICR), London, and the Royal Marsden NHS Foundation Trust involved 24 patients with tumours which were positive for EGFR - a key protein involved in cancer growth.
Typically, people were enrolled in the trial as a “last resort” because other treatments had failed.
The drug was able to act as a “warhead” targeted on the protein, without having to go through the complex process of re-engineering a patient’s own cells, researchers said.
Eight of the 24 patients in the trial responded to the immunotherapy and saw their cancers stop growing. Two patients with bowel cancer and one with lung cancer who received the immunotherapy in the ongoing trial saw their cancer shrink or stop growing for more than three months."
News 
Market Data 
Discover 
AI
